Nausea is dose-dependent
Increased energy expenditure must complement reduced food intake in order to maintain weight loss since physiological compensatory adaptations protect against major weight decrement: decreased caloric intake leads to increased hunger, lower sensitivity to satiety factors, and a reduced metabolic rate [83, 84]
Looking again at the CNICS cohort, Jimmy Ma, MD, of the University of Washington, and colleagues assessed the association between semaglutide use and liver fibrosis
When used with insulin or sulfonylureas, GLP-1 RAs may increase hypoglycaemia risk, requiring dose adjustments of these medications
In June 2021, the FDA approved Semaglutide (Wegovy), a GLP-1 receptor agonist developed by Novo Nordisk, for use as a weight loss drug
Communication is clear, avoiding the confusion common in medical programs